Rexahn's Akt inhibitor increases pancreatic cancer survival time 50%
This article was originally published in Scrip
Rexahn Pharmaceuticals potential first-in-class inhibitor of the Akt protein kinase in cancer cells, Archexin, provided metastatic pancreatic cancer with a survival rate that was more than 50% higher than historical rates for the standard of care. The data came from a 31-patient Phase IIa clinical trial. The Rockville, Maryland company will have to conduct a Phase IIb study in a larger pool of hard-to-treat patients to try to replicate the survival benefit.
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.